Publication
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.
Authors not recorded
Nat Commun2016PMID 26822383PMC4740184stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerCutaneous Melanomacivic_curation1.00
- drugAtezolizumabcivic_curation1.00
- drugNivolumabcivic_curation1.00
- drugPembrolizumabcivic_curation1.00
- geneHLA-DRAcivic_curation1.00
- variantHLA-DRA EXPRESSIONcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26822383
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| HLA-DRA EXPRESSION1 | ||||||||
| Atezolizumab + Nivolumab + PembrolizumabSubstitutes | Cutaneous MelanomaALIAS | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID985Melanoma patients treated with Anti-PD1 or anti-PD-L1(nivolumab, pembrolizumab, MPDL3280A) therapy were analyzed for expression of HLA-DRA (the primary antigen-presenting molecule of the MHC-II pathwa… (full text at CIViC) PMID 26822383 · Johnson et al., 2016 · Open in CIViC | civic |